LCZ696 + Sildenafil
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild to Moderate Hypertension
Conditions
Mild to Moderate Hypertension
Trial Timeline
Sep 1, 2012 → Jan 1, 2013
NCT ID
NCT01601470About LCZ696 + Sildenafil
LCZ696 + Sildenafil is a phase 2 stage product being developed by Novartis for Mild to Moderate Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01601470. Target conditions include Mild to Moderate Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01601470 | Phase 2 | Completed |
Competing Products
20 competing products in Mild to Moderate Hypertension